ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Eligibility Criteria

• 1. Ability to understand and willingness to sign an IRB-approved informed consent.
• 2. Age 18-64 years at the time of consent
• 3. Initial diagnosis of Acute Myeloid Leukemia (AML) per investigator Note: Date of initial diagnosis is the date of the bone marrow biopsy
• 4. Planned intensive induction chemotherapy Note: It is acceptable if chemotherapy has been initiated at the time of enrollment as long as it is within 4 weeks of diagnosis
• 5. Ability to read and understand the English and/or Spanish language(s)
• 6. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study.
• 1. Diagnosis of Acute Promyelocytic Leukemia
• 2. Unwilling to receive induction chemotherapy for AML
• 3. Previous treatment for hematologic malignancy
• 4. Prior allogeneic hematopoietic stem cell transplant